Gapping up
In reaction to strong earnings/guidance: OHGI +16.3%, WGBS +13.9%, FB +13.3%, UA +12.3%, TER+8.8%, MSTR +8.5%, MLNX +7.9%, HOG +6.7%, PYPL +6%, PYPL +6%, CAVM +5.9%, CRUS +5.9%,EURN +5.9%, DLB +5.7%, PHM +5.7%, CTXS +5.5%, CAT +4.9%, MJN +4.5%, DCOM +4.4%, GHL+3.9%, AMP +3.6%, CMRE +3.4%, BABA +3%, JBLU +2.7%, TXN +2.6%, BMY +2.5%, EPD +2.4%, CMO+2.3%, CCI +2.2%, FTK +2.2%, MCK +2.1%, HAR +1.9%, CY +1.9%, CHKP +1.8%, ZBH +1.8%, SNDK+1.7%, MEMP +1.5%, MEOH +1.5%, VLO +1.4%, LVS +1.3%, CAFD +1.2%, LLY +1.1%, DST +1.1%, F+1.1%, MYCC +1%, MKC +0.9%, MUR +0.8%, BLL +0.6%, .
M&A news: HTWR +7.2% (HeartWare and privately held Valtech Cardio terminate proposed acquisition, co to make $30 mln loan to Valtech), BIDU +1.3% (rumored to spin-off and IPO nine of its subsidiaries, according to Marbridge)
Select metals/mining stocks trading higher: MT +7.6%, BBL +2.4%, RIO +2.1%, BHP +1.6%
Other news: NEOS +59.2% (receives FDA approval for Adzenys XR-ODT), ETE +4.5% (maintained same dividend as Q3; Extends management fee to ETP through 2016; ETP maintains dividend, provided cap-ex update), INO +4.3% (beginning recruitment for its collaborative vaccine study for MERS), AMZN +3.7% (modestly rebounding from yday), SUNE +3.6% (cont strength), EXEL +3.5% (FDA deems NDA sufficiently complete and grants priority review for Cabozantinib), WLL +3.5% (still checking), MTL +3.3% (to create a Special Committee of the Board as part of efforts aimed at restructuring its debt portfolio), ETP +3% (maintained same dividend as Q3; Extends management fee to ETP through 2016; ETP maintains dividend, provided cap-ex update), NFLX+2.5% (modestly rebounding from yday), NKE +2.3% (in symp with UA), CNHI +2.1% (in symp with CAT), GPRO +2% (still checking), JD +1.7% (in symp with BABA), RDUS +1.2% (entered into a clinical collaboration with Novartis Pharmaceuticals (NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901 with investigational agent LEE011), AZN +0.9% (granted Breakthrough Therapy Designation by FDA for Lynparza for the
In reaction to strong earnings/guidance: OHGI +16.3%, WGBS +13.9%, FB +13.3%, UA +12.3%, TER+8.8%, MSTR +8.5%, MLNX +7.9%, HOG +6.7%, PYPL +6%, PYPL +6%, CAVM +5.9%, CRUS +5.9%,EURN +5.9%, DLB +5.7%, PHM +5.7%, CTXS +5.5%, CAT +4.9%, MJN +4.5%, DCOM +4.4%, GHL+3.9%, AMP +3.6%, CMRE +3.4%, BABA +3%, JBLU +2.7%, TXN +2.6%, BMY +2.5%, EPD +2.4%, CMO+2.3%, CCI +2.2%, FTK +2.2%, MCK +2.1%, HAR +1.9%, CY +1.9%, CHKP +1.8%, ZBH +1.8%, SNDK+1.7%, MEMP +1.5%, MEOH +1.5%, VLO +1.4%, LVS +1.3%, CAFD +1.2%, LLY +1.1%, DST +1.1%, F+1.1%, MYCC +1%, MKC +0.9%, MUR +0.8%, BLL +0.6%, .
M&A news: HTWR +7.2% (HeartWare and privately held Valtech Cardio terminate proposed acquisition, co to make $30 mln loan to Valtech), BIDU +1.3% (rumored to spin-off and IPO nine of its subsidiaries, according to Marbridge)
Select metals/mining stocks trading higher: MT +7.6%, BBL +2.4%, RIO +2.1%, BHP +1.6%
Other news: NEOS +59.2% (receives FDA approval for Adzenys XR-ODT), ETE +4.5% (maintained same dividend as Q3; Extends management fee to ETP through 2016; ETP maintains dividend, provided cap-ex update), INO +4.3% (beginning recruitment for its collaborative vaccine study for MERS), AMZN +3.7% (modestly rebounding from yday), SUNE +3.6% (cont strength), EXEL +3.5% (FDA deems NDA sufficiently complete and grants priority review for Cabozantinib), WLL +3.5% (still checking), MTL +3.3% (to create a Special Committee of the Board as part of efforts aimed at restructuring its debt portfolio), ETP +3% (maintained same dividend as Q3; Extends management fee to ETP through 2016; ETP maintains dividend, provided cap-ex update), NFLX+2.5% (modestly rebounding from yday), NKE +2.3% (in symp with UA), CNHI +2.1% (in symp with CAT), GPRO +2% (still checking), JD +1.7% (in symp with BABA), RDUS +1.2% (entered into a clinical collaboration with Novartis Pharmaceuticals (NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901 with investigational agent LEE011), AZN +0.9% (granted Breakthrough Therapy Designation by FDA for Lynparza for the